ONL Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Michigan, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
524 S Main St Ste 110, Ann Arbor, Michig...Phone Number
(734) 412-8787Website
www.onltherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About ONL Therapeutics
Founded in 2011, ONL Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing innovative therapeutics to protect and improve the vision of patients with a range of retinal disease and conditions. ONL Therapeutics is located in MichiganExplore more
ONL Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ONL Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if ONL Therapeutics is spiking on competitors!
Click to see if ONL Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at ONL Therapeutics
Funding: Get notified immidiatlly once ONL Therapeutics has new funding data
Earning: See what the market has to say on ONL Therapeutics recently announced quarterly report
Check if ONL Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when ONL Therapeutics launches new products
ONL Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to ONL Therapeutics
Compare insights from companies similar to ONL Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ONL Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ONL Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ONL Therapeutics.
ONL Therapeutics financials insights
Gather financial insights about ONL Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Angel/Seed
$501K
2016
Debt
$916K
2017
Series A
$4.3M
2022
Series B
$46.9M
2023
Series C
$15M
2024
Series D
$65M
ONL Therapeutics Tech Stack
A closer look at the technologies used by ONL Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Funding
New Hire
Executive Move
ONL Therapeutics News & Media
ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science
Xelafaslatide was safe and well tolerated at all evaluated doses, with the potential to reduce GA lesion growth and improve vision Xelafaslatide was safe and well tolerated at all evaluated doses, with the potential to reduce GA lesion growth and improve visionONL Therapeutics to Present at EYENOVATE and the FLORetina–ICOOR Congress 2025
ANN ARBOR, Mich., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will deliver podium presentations at EYENOVATE and the FLORetina-ICOOR Congress 2025. This is the inaugural year for EYENOVATE, which will be held on December 4, 2025. The FLORetina-ICOOR Congress 2025 will be held from December 4-7, 2025. Both meetings will beONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD
Approvals received from World Health Organization and United States Adopted Names Council establishing “xelafaslatide” as nonproprietary name for ONL1204 Ophthalmic Solution Approvals received from World Health Organization and United States Adopted Names Council establishing “xelafaslatide” as nonproprietary name for ONL1204 Ophthalmic SolutionONL Therapeutics Announces Multiple Presentations at Leading Ophthalmology Meetings
ANN ARBOR, Mich., Feb. 04, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will present clinical data and scientific research at the following first quarter meetings:
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ONL Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2011, ONL Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing innovative therapeutics to protect and improve the vision of patients with a range of retinal disease and conditions. ONL Therapeutics is located in Michigan... Read More
